Join Growin Stock Community!

三鼎生技6808.TW Overview

TW StockBiotech. & Medical
(No presentation for 6808)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

三鼎生技（6808）Overall Performance

三鼎生技（6808）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

三鼎生技（6808） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

三鼎生技（6808）Key Information

三鼎生技（6808）Profile

3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts professional research. It offers artificial bone substitute, skull fixation system, biological dressings, bio inks, and bioprinting equipment, as well as orthopedic, tooth and jaw, and skull reconstruction products, and scalp care products. It serves medical centers, research institutions, and companies and distributors to establish an interdisciplinary alliance encompassing industry, government, academia, research, and medicine. The company was founded in 2014 and is based in New Taipei City, China.

三鼎生技（6808）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.98
PE Ratio (TTM)
40.45
Forward PE
-
PS Ratio (TTM)
8.89
PB Ratio
3.39
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
66.82%
Net Margin
21.98%
Revenue Growth (YoY)
1297.76%
Profit Growth (YoY)
5008.70%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.98
PE Ratio (TTM)
40.45
Forward PE
-
PS Ratio (TTM)
8.89
PB Ratio
3.39
Price-to-FCF
-
Gross Margin
66.82%
Net Margin
21.98%
Revenue Growth (YoY)
1297.76%
Profit Growth (YoY)
5008.70%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6808

三鼎生技

39.45D

-2.28%

(-0.02)

  • When is 6808's latest earnings report released?

    The most recent financial report for 三鼎生技 (6808) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6808's short-term business performance and financial health. For the latest updates on 6808's earnings releases, visit this page regularly.

  • Where does 6808 fall in the P/E River chart?

    According to historical valuation range analysis, 三鼎生技 (6808)'s current price-to-earnings (P/E) ratio is 34.2, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • How much cash does 6808 have?

    At the end of the period, 三鼎生技 (6808) held Total Cash and Cash Equivalents of 55.49M, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6808 go with three margins increasing?

    In the latest report, 三鼎生技 (6808) achieved the “three margins increasing” benchmark, with a gross margin of 81.76%%, operating margin of 33.42%%, and net margin of 39.34%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6808's profit trajectory and future growth potential.